Q4081 Epoetin alfa, 100 units esrdInjection, epoetin alfa, 100 units (for esrd on dialysis)
Q4081 payment limit: $0.667 per 100 UNITS, effective October 1, 2026 through December 31, 2026, based on 2Q26 ASP data. Coinsurance 20%.
55513-0126-10 Epogen, Amgen Inc: 200 billing units per package (10 VIAL in 1 PACKAGE / 1 mL in 1 VIAL)55513-0126-20 Epogen, Amgen Inc: 200 billing units per package (10 VIAL in 1 PACKAGE / 1 mL in 1 VIAL)55513-0144-10 Epogen, Amgen Inc: 1000 billing units per package (10 VIAL in 1 PACKAGE / 1 mL in 1 VIAL)55513-0148-10 Epogen, Amgen Inc: 400 billing units per package (10 VIAL in 1 PACKAGE / 1 mL in 1 VIAL)55513-0267-10 Epogen, Amgen Inc: 300 billing units per package (10 VIAL in 1 PACKAGE / 1 mL in 1 VIAL)55513-0267-20 Epogen, Amgen Inc: 300 billing units per package (10 VIAL in 1 PACKAGE / 1 mL in 1 VIAL)55513-0283-10 Epogen, Amgen Inc: 2000 billing units per package (10 VIAL in 1 PACKAGE / 2 mL in 1 VIAL)55513-0283-20 Epogen, Amgen Inc: 2000 billing units per package (10 VIAL in 1 PACKAGE / 2 mL in 1 VIAL)55513-0478-10 Epogen, Amgen Inc: 2000 billing units per package (10 VIAL in 1 PACKAGE / 1 mL in 1 VIAL)55513-0478-20 Epogen, Amgen Inc: 2000 billing units per package (10 VIAL in 1 PACKAGE / 1 mL in 1 VIAL)59676-0302-01 Procrit, Janssen Products, LP: 120 billing units per package (6 VIAL, SINGLE-DOSE in 1 CARTON / 1 mL in 1 VIAL, SINGLE-DOSE)59676-0303-01 Procrit, Janssen Products, LP: 180 billing units per package (6 VIAL, SINGLE-DOSE in 1 CARTON / 1 mL in 1 VIAL, SINGLE-DOSE)59676-0304-01 Procrit, Janssen Products, LP: 240 billing units per package (6 VIAL, SINGLE-DOSE in 1 CARTON / 1 mL in 1 VIAL, SINGLE-DOSE)59676-0310-01 Procrit, Janssen Products, LP: 600 billing units per package (6 VIAL, SINGLE-DOSE in 1 CARTON / 1 mL in 1 VIAL, SINGLE-DOSE)59676-0310-02 Procrit, Janssen Products, LP: 2500 billing units per package (25 VIAL, SINGLE-DOSE in 1 CARTON / 1 mL in 1 VIAL, SINGLE-DOSE)59676-0312-04 Procrit, Janssen Products, LP: 800 billing units per package (4 VIAL, MULTI-DOSE in 1 CARTON / 2 mL in 1 VIAL, MULTI-DOSE)59676-0320-04 Procrit, Janssen Products, LP: 800 billing units per package (4 VIAL, MULTI-DOSE in 1 CARTON / 1 mL in 1 VIAL, MULTI-DOSE)59676-0340-01 Procrit, Janssen Products, LP: 1600 billing units per package (4 VIAL, SINGLE-DOSE in 1 CARTON / 1 mL in 1 VIAL, SINGLE-DOSE)Status E: excluded from the PFS by regulation.
22 of 23 payer prior-auth lists that name Q4081 require prior authorization or set conditions: Aetna, Blue Cross Blue Shield of Arizona (AZ Blue), Blue Cross and Blue Shield of Texas, Cigna, Humana, Molina Healthcare of Texas.
Q4081 appears in 17 coverage policies from Aetna, Blue Cross & Blue Shield of Mississippi, BlueCross BlueShield of South Carolina, Centene, Cigna, Premera Blue Cross, UnitedHealthcare, Wellmark Blue Cross Blue Shield.
| Payer | Policy | Role in policy | Reviewed | Document |
|---|---|---|---|---|
| Aetna | Acute Ischemic Stroke Treatments (0789) Cerebrolysin, Transdermal glyceryl trinitrate, Statins (e.g. simvastatin) | not covered | Nov 19, 2025 | payer document |
| Aetna | Diabetic Neuropathy: Selected Treatments (0729) Fulranumab, Ozone Therapy, Ghrelin, Interleukin - 6, mecobalamin (a vitamin B12 analog), pulsed magnetic field treatment | not covered | Feb 24, 2026 | payer document |
| Aetna | Erythropoiesis Stimulating Agents (0195) | covered if criteria are met | Jan 20, 2026 | payer document |
| Aetna | Hypoxic Ischemic Encephalopathy (0812) Topiramate | not covered | Nov 20, 2025 | payer document |
| Aetna | Injectable Medications (0020) | listed, no stance (range Q4081-Q4086) | Mar 5, 2026 | payer document |
| Aetna | Intravenous Iron Therapy (0575) | listed, no stance | Jul 1, 2026 | payer document |
| Blue Cross & Blue Shield of Mississippi | Erythropoiesisstimulating Agents (S.5.01.423) | listed, no stance | payer document | |
| Blue Cross & Blue Shield of Mississippi | Erythropoiesisstimulating Agents (L.5.01.423) | listed, no stance | payer document | |
| BlueCross BlueShield of South Carolina | Erythopoiesis Stimulating Agents and Darbepoetin Alfa (Aranesp) (CAM 50104) | listed, no stance | Jan 1, 2026 | payer document |
| Centene | Epoetin Alfa (Epogen, Procrit), Epoetin Alfa-epbx (Retacrit) Reference Number: CP.PHAR.237 (CP.PHAR.237) | covered if criteria are met | May 1, 2026 | payer document |
| Cigna | Erythropoiesis-Stimulating Agents – Epoetin Alfa Products (IP0296) | covered if criteria are met | Sep 1, 2026 | payer document |
| Premera Blue Cross | Erythropoiesis-Stimulating Agents (5.01.535) | listed, no stance | Jun 8, 2026 | payer document |
| UnitedHealthcare | Erythropoiesis-Stimulating Agents (CS2026D0028R) | listed, no stance | Apr 1, 2026 | payer document |
| UnitedHealthcare | Erythropoiesis-Stimulating Agents (2026D0028Y) | listed, no stance | Apr 1, 2026 | payer document |
| UnitedHealthcare | Erythropoiesis-Stimulating Agents (for Indiana Only) (CSIND0028.06) | listed, no stance | Apr 1, 2025 | payer document |
| UnitedHealthcare | Erythropoiesis-Stimulating Agents (for Ohio Only) (CSOH2026D0028.C) | listed, no stance | Mar 1, 2026 | payer document |
| Wellmark Blue Cross Blue Shield | Erythropoiesis Stimulating Agents (05.04.25) | listed, no stance | Jan 1, 2026 | payer document |
From payers' published prior-auth lists, coverage policies and state Medicaid fee schedules, updated Oct 16, 2026. The role is what the policy's own code table or text says about the code. Not a guarantee of coverage or payment; verify with the payer. CPT® is a registered trademark of the American Medical Association.